MediWound Ltd.
MDWD Real Time Price USDRecent trades of MDWD by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by MDWD's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Debriding composition for treating wounds Jul. 12, 2022
-
Patent Title: Proteolytic extract from bromelain for the treatment of connective tissue disorders May. 21, 2019
-
Patent Title: Proteolytic extract from bromelain for the treatment of connective tissue disorders Dec. 06, 2016
-
Patent Title: Debriding composition from bromelain and methods of production thereof Sep. 24, 2013
-
Patent Title: Debriding composition from bromelain and methods of production thereof Feb. 21, 2012
-
Patent Title: Apparatus and methods for enzymatic escharotomy in burn induced compartment syndrome Sep. 14, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of MDWD in WallStreetBets Daily Discussion
Recent insights relating to MDWD
Recent picks made for MDWD stock on CNBC
ETFs with the largest estimated holdings in MDWD
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view MDWD Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.